Fortis Inc. closed 2.6% below its 52-week high of C$64.39, which the company reached on February 14th.

In a report released yesterday, Maurice Choy from RBC Capital maintained a Hold rating on Fortis (FTS – Research Report), with a price target ...

Wells Fargo analyst Neil Kalton maintained a Hold rating on Fortis (FTS – Research Report) on February 14 and set a price target of C$66.00.

Fortis Inc. closed 2.9% short of its 52-week high of C$64.39, which the company achieved on February 14th.

Upcoming trends in ADC therapeutics, including their use in autoimmune conditions and the dawn of bispecific designs, are revolutionizing the landscape of targeted therapy. These innovations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

that it licensed last year from Fortis Therapeutics. At this year's ASCO, positive data was reported from an investigator-led phase 1b study that looked at the combination of FG-3246 with Pfizer ...

Earnings were up at Fortis in the fourth quarter of the year. Profit rose to $396-million, up from $381-million the same time last year. The St. John’s-based electric and gas utility says the profit ...

Fortis Healthcare Limited (FHL) is one of the largest healthcare services providers in India with 27 hospitals ~4500 operational beds and over 426 diagnostics centres as of 31 March 2023. The Company ...

Rights Aug 18, 2009 Aug 20, 2009 Dec 24, 2008 Rights ratio: 2 share for every 5 held at a price of Rs 110.0 Rights-Aug 20, 2009 Aug 10, 2009 Rights ratio: 2 share for every 5 held at a price of Rs 110 ...

After hours: February 21 at 6:55:44 PM EST Loading Chart for ABEO ...